Pulmatrix Reaches Merger Agreement With Cullgen; Shares Jump

MT Newswires Live2024-11-13

Pulmatrix (PULM) said Wednesday it has reached a merger agreement with Cullgen, a clinical-stage biopharma focused on targeted protein degradation for cancer and other diseases.

The merger, expected to close by March 2025, includes Pulmatrix shareholders receiving a special cash dividend based on the company's net cash exceeding $2.5 million at closing, the company said.

Upon closing, Pulmatrix stockholders will own 3.6% of the combined company, which will operate as Cullgen Inc. and be listed on Nasdaq. Pre-merger Cullgen stockholders will own the remaining stake.

Cullgen Chief Executive Ying Luo will lead the executive officers of the combined company, which is expected to have cash and cash equivalents of up to $65 million, Pulmatrix said.

Shares of Pulmatrix jumped more than 35% in recent trading.

Price: 2.79, Change: +0.73, Percent Change: +35.44

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment